Thomas Guiot

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 348 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

Kristoff Muylle, Patrick Flamen, Daniëlle J. Vugts et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 104 citations · Full text

Medicine, Nuclear Medicine, Radiology +15

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials

Nicolas Charette, Caroline Vandeputte, Lieveke Ameye et al. · BMC Cancer · 2019 · 104 citations · Full text

Medicine, Oncology, Radiology +16

Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study

Hugo Levillain, Ivan Duran Derijckere, Lieveke Ameye et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 76 citations · Full text

Medicine, Oncology, Radiology +14

A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours

Gwennaëlle Marin, Bruno Vanderlinden, Ioannis Karfis et al. · Physica Medica · 2018 · 65 citations · Full text

Medicine, Nuclear Medicine, Oncology +17